Why Alligator Bioscience stock moves
Alligator Bioscience fell slightly, more than the market.
Written after the close on ·
Why today
16,307 news analyzed todayAlligator Bioscience fell slightly, more than the market.
The company's share count rose sharply and a reverse split was proposed, which likely weighed on sentiment.
Over the last five trading days the stock was roughly unchanged, while OMX Stockholm 30 was also flat.
Short positions, bets against the stock, rose through the period.
Next, the company reports results on Thursday 11 February 2027.
Today's move of −2.88% was 0.7 times a normal day's 4.4%. OMX Stockholm 30 moved −1.01% on the same day.
Alligator Bioscience −2.88%OMX Stockholm 30 −1.01%Much weaker than the market
What analysts expect, and how often they have been right
Analysts’ estimates for Alligator Bioscience.
Price targets
Latest price 0.01 SEK
People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor. No reported trades in the past year.
Has the share price followed the business?
Price and earnings moved in the same direction: 0 out of 3 years. Across Nordic companies, that happens in about 60% of years. In 2025, the price changed −98% and earnings per share went from -5.26 SEK to -1.27 SEK.
Revenue, profit and market cap
RevenueProfitMarket capHatched bars: analysts’ estimates.bn SEK
Assets, liabilities and market cap
AssetsLiabilitiesMarket capbn SEK
Price and earnings moved in the same direction: 0 out of 3 years.Market cap (Now): 36.0 m SEKRevenue 2025: 0.5 m SEK
What the key figures say about Alligator Bioscience
The figures connect what Alligator Bioscience earns with what investors pay.
The line shows the share price in the same year, on its own scale. Hatched bars: analysts’ estimates.
Profit divided by the number of shares. Each share represents this much of the earnings.
2022–2025: -24.58 SEK–-1.27 SEK. Peers: Strategic Partners 31.00 DKK, Annexin Pharmaceuticals -6.20 SEK, Active Biotech -1.70 SEK.
What the company sold during the year.
2022–2025: 0.5 m SEK–58.1 m SEK. Peers: Strategic Partners 0.3 m DKK. 2026 estimate: 1.2 m SEK (1.2 m SEK–1.2 m SEK).
The percentage of revenue left after the costs of running the business.
2022–2025: −23669.3%–−328.4%. Peers: Strategic Partners −791.6%.
Profit as a percentage of shareholders’ money in the company.
2022–2025: −2096.9%–−217.2%. Peers: Strategic Partners 7.2%, Annexin Pharmaceuticals −176.1%, Active Biotech −140.6%.
What investors pay for each unit the company sells.
2022–2025: 9.91–479.87. Peers: Strategic Partners 104.13. 2026 estimate: 30.03.
More key figures
Market cap divided by shareholders’ equity, what remains after liabilities.
2022–2025: 11.62–115.77. Peers: Strategic Partners 1.26, Annexin Pharmaceuticals 6.29, Active Biotech 1.71.
Cash left after investments, divided by the number of shares.
2022–2025: -13.28 SEK–-0.22 SEK. Peers: Strategic Partners -39.47 DKK, Annexin Pharmaceuticals -4.66 SEK, Active Biotech -1.23 SEK.
The percentage of assets financed by shareholders’ equity.
2022–2025: −125.2%–52.5%.
What to watch next, and why
The earnings report shows how Alligator Bioscience's revenue and profit have changed.
- Earnings report
The earnings report shows how Alligator Bioscience's revenue and profit have changed.
Add to calendar
More about Alligator Bioscience
Insider trades
People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor.
No reported trades in the past year.
Earnings report
Next report: · Add to calendar · Google Calendar
On its last 16 report days Alligator Bioscience usually moved about 7.8%. On a normal day it moves 4.4%.
−1.85% +22.26% +0.47% −4.07%
10,000 SEK in Alligator Bioscience bought on November 23, 2016 is worth 0 SEK today, with dividends reinvested.
The same amount in OMX Stockholm 30 with dividends would have become 29,300 SEK.
What would 10,000 SEK in Alligator Bioscience be worth today? →
What would 10,000 SEK in Alligator Bioscience be worth today?
0 SEK
with dividends reinvested, bought on November 23, 2016. The same amount in OMX Stockholm 30 with dividends would have become 29,300 SEK.
At worst it was worth 0 SEK (October 6, 2026).
The five biggest days of the journey
· +260.8% · the whole market fell 0.1% the same day
· +195.4% · the whole market rose 1.4% the same day
· +76.2% · the whole market rose 0.9% the same day
· −74.0% · the whole market fell 0.6% the same day
· −74.0% · the whole market rose 0.3% the same day
Earlier days
+2.02% market −0.11% Alligator Bioscience was roughly unchanged over the week, while OMX Stockholm 30 was also roughly flat, so it moved about with the market. Read →
Alligator Bioscience was roughly unchanged over the week, while OMX Stockholm 30 was also roughly flat, so it moved about with the market.
The week's main company news was the sale of its mitazalimab cancer drug to Biossil on Monday 2 November, which gives it an upfront payment and possible milestone payments.
The next earnings report is Thursday 11 February 2027.
−3.60% market +0.83% Alligator Bioscience fell as Fenja Capital reported a stake sale. Read →
Alligator Bioscience fell as Fenja Capital reported a stake sale.
The stock fell clearly while the OMX Stockholm 30 rose clearly, so it moved against the market.
Fenja Capital, the main shareholder, reported selling shares on November 3, cutting its stake to about 14.7%.
Over the last five trading days the shares rose slightly, more than the OMX Stockholm 30, which also rose slightly.
Trading volume was about three times its usual level, and the day's move was within its usual daily range.
−11.20% market −0.08% Alligator Bioscience fell sharply. Read →
Alligator Bioscience fell sharply.
No company news from that session clearly explains the drop, so the cause is unclear.
Over the last five trading days the shares were roughly unchanged, while OMX Stockholm 30 rose slightly.
Trading volume was about five times its usual level, so the drop drew heavy activity.
Earlier news includes the sale of the mitazalimab drug rights to Biossil, the share count rise after the rights issue, and a proposed 1-for-1,000 reverse share split to be voted on at a meeting on 27 November 2026.
+26.26% market +0.48% Alligator Bioscience rose on the Mitazalimab sale to Biossil. Read →
Alligator Bioscience rose on the Mitazalimab sale to Biossil.
The stock moved well beyond the market, which rose only slightly.
The sale gives Alligator a small upfront payment with milestone payments and royalties to follow.
Over the last five trading days the shares rose sharply, also well ahead of the market.
Short positions also rose through October, and a 1-for-1,000 reverse share split is up for a vote on November 27.
−1.00% market −0.29% Alligator Bioscience moved little, while the Stockholm market fell slightly. Read →
Alligator Bioscience moved little, while the Stockholm market fell slightly.
The stock was roughly unchanged in the last session, an ordinary move for the stock.
Over the last five trading days the stock was roughly unchanged, while OMX Stockholm 30 rose clearly.
No company news from the last session explains the move, so the day looks ordinary.
Watch for the extraordinary general meeting on 27 November 2026, which will vote on the reverse share split.
−1.98% market +3.01% Alligator Bioscience was roughly unchanged over the week and moved less than the market. Read →
Alligator Bioscience was roughly unchanged over the week and moved less than the market.
The market's main index rose clearly over the same days, so the share lagged behind it.
Company news was mostly administrative.
The share count rose after the rights issue.
−0.99% market +0.41% Alligator Bioscience was roughly unchanged without company news. Read →
Alligator Bioscience was roughly unchanged without company news.
Over the same day OMX Stockholm 30 rose slightly, so the stock moved less than the market.
Over the last five trading days the shares fell slightly while the market rose sharply, so the stock moved against it.
The move was ordinary for this stock.
Recent news includes a proposed reverse share split of 1,000 old shares into one, to be voted on at a meeting on 27 November.
−9.01% market +0.33% Alligator Bioscience fell sharply without a company-news explanation. Read →
Alligator Bioscience fell sharply without a company-news explanation.
Alligator Bioscience fell sharply in the last session, while the OMX Stockholm 30 rose slightly, so it moved against the market.
Trading was about twice a normal day, and the stock sits near its lowest close of the past year.
Over the last five trading days it fell slightly, also against a slightly rising market.
The most likely background is the company's ongoing wind-down of its mitazalimab project and its recent rights issue, which brought in SEK 58.8 million before costs.
+3.74% market +0.96% Alligator Bioscience rose clearly without a company-news explanation. Read →
Alligator Bioscience rose clearly without a company-news explanation.
The stock moved more than the broader market, which also rose clearly that day.
Over the last five trading days, the shares slipped slightly while OMX Stockholm 30 was roughly flat.
Trading volume was well above normal, about three times a usual session, which suggests heavy interest.
The most likely driver is the recent wave of short-position increases, meaning more traders betting on a fall, which can force some to buy back shares and lift the price.
+5.94% market +1.57% Alligator Bioscience rose as Fenja Capital bought shares. Read →
Alligator Bioscience rose as Fenja Capital bought shares.
Alligator Bioscience rose clearly in the last trading day, moving more than the market.
Over the last five trading days it fell clearly, a big move for this stock.
The most likely reason for the rise is a disclosure showing Fenja Capital II bought shares on 8 October, lifting its stake to 19.7 percent.
Trading volume was about twice a normal session.
−4.72% market +0.41% Alligator Bioscience fell clearly, with no clear company news explaining it. Read →
Alligator Bioscience fell clearly, with no clear company news explaining it.
Over the last five trading days the shares fell sharply, a much bigger drop than the market's, which is a big move for this stock.
In the last session the stock moved against OMX Stockholm 30, which rose slightly, and trading volume was well above its usual level.
Redeye's analyst published a research update on the company's Q3 report, but it offers no new figures, so it does not clearly explain the drop.
The most likely background is the company's wind-down of its own drug development and its heavy dilution from the rights issue, which the market is still digesting.
−23.48% market −3.67% Alligator Bioscience fell sharply over the last five trading days, a much bigger drop than the OMX Stockholm 30 market index. Read →
Alligator Bioscience fell sharply over the last five trading days, a much bigger drop than the OMX Stockholm 30 market index.
The move was big for this stock, rare in the past year.
Likely drivers were the company's Q3 report, which showed a refocus on its HLX22 partner programme (a drug in late-stage trials that others pay for) and a share issue that brought in SEK 58.8 million (new shares sold to existing owners to raise cash).
Trading was very heavy yesterday, and the shares sit near their one-year low.
Learn more · Why do stocks go up and down?